Faster Trials, Fewer Licences: How India Is Rewiring Drug Regulation to Accelerate Pharma R&D

Under the earlier framework, pharmaceutical companies were required to obtain a test licence from the Central Drugs Standard Control Organization (CDSCO) to manufacture small quantities of drugs for purposes such as examination, testing, research, or analysis—even when there was no commercial intent.

The amended rules replace this requirement with a simple online intimation to CDSCO for most categories of non-commercial manufacture. Once the intimation is submitted, companies may proceed with development activities without waiting for explicit regulatory clearance.

However, the reform preserves stricter oversight for a narrow set of high-risk drugs, including cytotoxic drugs, narcotic drugs, and psychotropic substances, for which test licences will continue to be mandatory.

According to the Health Ministry, this single change is expected to save at least 90 days in the drug development life cycle, removing a recurrent bottleneck in early-stage pharmaceutical research.

Even Where Licences Remain, Timelines Are Halved

For categories where test licences are still required, the amendments substantially compress regulatory timelines. The statutory processing period has been reduced from 90 days to 45 days, cutting approval time in half.

The scale of impact is significant. CDSCO processes an estimated 30,000 to 35,000 test licence applications every year. By eliminating or accelerating approvals for a large share of these applications, the reform is expected to materially reduce compliance costs and delays across the industry, particularly for research-driven and generic drug manufacturers.

Clinical Research Boost: BA/BE Studies Get a Fast Track

A second major reform targets Bioavailability and Bioequivalence (BA/BE) studies, which are critical for the development and approval of generic medicines. Until now, even certain low-risk BA/BE studies required prior regulatory permission before initiation.

Under the amended rules, select categories of low-risk BA/BE studies can now commence on the basis of online intimation alone, without waiting for prior approval from CDSCO. This is especially consequential for India’s generic pharmaceutical sector, where speed-to-study often determines competitiveness in both domestic and export markets.

CDSCO handles roughly 4,000 to 4,500 BA/BE study applications annually. The Ministry expects the revised mechanism to sharply reduce procedural delays and enable faster study initiation, shortening the overall timeline from laboratory development to market entry.

Why 90 Days Matters: The Real Cost of Regulatory Latency in Pharma R&D

In pharmaceutical development, time lost to regulation is rarely neutral—it compounds across the development chain. A 90-day delay at the test-licence or BA/BE stage typically cascades into longer timelines for dossier preparation, manufacturing scale-up, and export market filings. Industry estimates from Indian generic manufacturers and contract research organisations (CROs) suggest that each quarter of delay can raise development costs by 8–12%, largely through extended laboratory occupancy, repeated stability studies, and idle clinical infrastructure.

For generic drugs, the stakes are especially high. Entry timing often determines market share, particularly in the United States and Europe, where first-wave generic entrants capture disproportionate revenues after patent expiry. Studies cited by the US Food and Drug Administration (FDA) show that the first approved generic can secure 180-day exclusivity in certain categories, while later entrants face sharply compressed margins. Even for non-exclusive markets, delays reduce the window to amortise development costs before price erosion sets in.

By replacing approval with intimation for low-risk studies, the amendments effectively pull forward research activity by an entire quarter—an adjustment that materially improves cash-flow predictability and project sequencing.

Digital Implementation: NSWS and SUGAM at the Core

To operationalise the new regime, the government will roll out dedicated online modules on the National Single Window System (NSWS) and the SUGAM portal. These platforms will allow companies to submit intimations digitally, track submissions transparently, and reduce reliance on manual processing.

From a regulatory perspective, the shift is also intended to improve efficiency within CDSCO itself. By reducing the volume of applications requiring detailed scrutiny, the regulator can optimise manpower deployment and focus oversight on higher-risk drugs and clinical activities.

Global Benchmarking: How India Is Quietly Catching Up with the FDA and EMA

The NDCT amendments also mark a subtle but important convergence with global regulatory practice. In the United States, the FDA permits a wide range of exploratory and non-clinical research activities without prior approval, provided they fall below defined risk thresholds. Many early-stage manufacturing activities proceed under Investigational New Drug (IND) exemptions or notification-based mechanisms, with enforcement focused on inspections and post-hoc compliance.

Similarly, under the European Union framework overseen by the European Medicines Agency (EMA), Bioequivalence studies for generics are largely decentralised. Sponsors notify or seek ethics approvals at the member-state level, while centralised authorisation is reserved for higher-risk or innovative products. This structure prioritises speed and proportionality, particularly for routine generic development.

By contrast, India’s earlier regime required central permissions even for non-commercial manufacture and low-risk BA/BE studies, making it comparatively permission-heavy. Industry representations to the Health Ministry over the past decade repeatedly highlighted this divergence as a deterrent for global sponsors considering India for early-stage research.

The new intimation-based approach brings India closer to International Council for Harmonisation (ICH) and World Health Organization (WHO) principles of risk-based oversight, where regulatory intensity is matched to patient exposure and systemic risk. While India still retains stricter controls for cytotoxic, narcotic, and psychotropic substances, the overall direction signals regulatory maturity rather than deregulation.

Who Gains the Most—and Who Doesn’t

The benefits of the amendments are not evenly distributed across the pharmaceutical ecosystem. Generic drug manufacturers, especially mid-sized Indian firms with export exposure, stand to gain the most. Faster BA/BE initiation directly improves their ability to synchronise Indian development timelines with overseas filing calendars, particularly for the US and EU markets.

Contract Research Organisations (CROs) are another major beneficiary. India hosts a large CRO base concentrated in clusters such as Hyderabad, Ahmedabad, Mumbai, and Bengaluru, where laboratory and clinical infrastructure is often booked months in advance. Removing approval bottlenecks improves utilisation rates and reduces downtime, strengthening India’s position in the global CRO value chain.

Academic institutions and publicly funded research labs also benefit, as non-commercial manufacture for examination and analysis can now proceed without prolonged regulatory waits. This lowers entry barriers for translational research and early proof-of-concept work.

By contrast, firms working on biologics, novel chemical entities, gene therapies, or high-risk drug categories will see limited immediate relief. These areas remain subject to full licensing and scrutiny due to patient-safety considerations. Large multinational innovators, whose pipelines are already structured around global approvals, gain marginally compared to generics-focused players.

The Implementation Risk: Where Friction Could Re-Enter the System

While the amendments materially simplify the rulebook, their success hinges on execution. The new regime depends heavily on the reliability and interoperability of digital platforms such as NSWS and SUGAM. Past experience with regulatory portals suggests that system downtime, unclear data fields, or inconsistent state-level integration can reintroduce delays even when formal approvals are removed.

Another risk is the emergence of informal gatekeeping. Even under an intimation model, industry participants warn that ambiguous guidance notes or unwritten expectations could lead to “soft approvals” being sought in practice, undermining the reform’s intent. Clear standard operating procedures and published FAQs will be critical to prevent interpretive uncertainty.

Finally, the shift toward post-intimation oversight places greater demands on CDSCO’s inspection and audit capacity. If manpower and technical resources are not redeployed effectively, the regulator could face backlogs in monitoring compliance, potentially triggering corrective tightening in the future.

In short, the reform reduces front-end friction but raises the stakes for backend regulatory capacity. Whether India realises the full benefits will depend on sustained administrative discipline, transparent guidance, and credible enforcement.

Why This Matters

The amendments signal a broader recalibration of India’s drug regulatory philosophy—from process-heavy ex ante controls to risk-based, technology-enabled oversight. By removing mandatory approvals for low-risk, non-commercial research and routine BA/BE studies, the government is attempting to align domestic rules more closely with global best practices while preserving safeguards where risks are highest.

For industry, the impact is tangible: shorter development cycles, lower compliance costs, and faster initiation of research and clinical studies. For India’s pharmaceutical ecosystem—particularly generics, contract research organisations, and innovation-led firms—the reforms strengthen the country’s case as a preferred global hub for pharmaceutical R&D.

Crucially, the changes also reflect an administrative trade-off: fewer front-end permissions in exchange for better-targeted regulatory scrutiny. Whether this balance delivers sustained gains will depend on implementation, but the amendments mark one of the most consequential procedural resets in India’s drug regulation framework since the NDCT Rules were introduced in 2019.